HomeAI · summaries
Storia in 3 fonti
Kardigan targets IPO to support cardiology pipeline progression - Pharmaceutical Technology
Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Cardio drugmaker Kardigan plans to go public
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.
- ·
endpoints.news
Kardigan readies Nasdaq IPO to back three cardio drugs
Cardiology biotech Kardigan filed for a Nasdaq IPO under ticker {$KARD}, joining a growing roster of clinical-stage drug developers tapping reopened capital markets.
